ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
At the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) Andrew Wagner (Dana-Farber Cancer…
Author ONA Webmaster
ONA Webmaster
Creating outstanding digital resources tailored for the Australian Oncology community, including independent news and a dedicated job portal.
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
At the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) David Reardon, MD, director…
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
Real-world data shows that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related…
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
For cancer survivors experiencing overall mood disturbance, anxiety, fatigue, or insomnia, regular gentle hatha and…
ASCO 2026: Fasting before and after chemo may help improve treatment response for some people with ovarian cancer
A new study based in Italy found that fasting before and after chemotherapy sessions, when…
ASCO 2026: Less cognitive decline with darolutamide treatment than enzalutamide in people with advanced prostate cancer
Results from the phase 2 ARACOG study, the first direct comparison of the cognitive effects…
ASCO 2026: Trial tests virus-immunotherapy combination for neuroendocrine tumours
A phase I clinical trial is testing whether a tumour-targeting virus can help immunotherapy work…
ASCO 2026: New AI tool may help personalise multiple myeloma treatment
An artificial intelligence-based tool may help physicians determine which newly diagnosed multiple myeloma patients are…
OCRF opens 2027 national research grants to advance ovarian cancer research
The Ovarian Cancer Research Foundation’s (OCRF) National Research Grants Program is now accepting Expression of…
The PBS Update: March 2026
PBS UPDATE SERIES 1 / EPISODE 1 The PBS Update Podcast: March 2026 Welcome to…